Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Purchased by Bleakley Financial Group LLC

Bleakley Financial Group LLC raised its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 250.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 39,993 shares of the company’s stock after acquiring an additional 28,589 shares during the period. Bleakley Financial Group LLC’s holdings in Compass Therapeutics were worth $58,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the last quarter. Barclays PLC lifted its holdings in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares in the last quarter. Catalina Capital Group LLC acquired a new stake in Compass Therapeutics during the 4th quarter valued at approximately $71,000. The Manufacturers Life Insurance Company bought a new stake in shares of Compass Therapeutics in the third quarter worth $79,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Compass Therapeutics in the 2nd quarter valued at about $41,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $3.75 on Thursday. The firm’s 50 day simple moving average is $2.20 and its 200-day simple moving average is $1.77. The company has a market cap of $515.96 million, a P/E ratio of -10.13 and a beta of 1.17. Compass Therapeutics, Inc. has a fifty-two week low of $0.76 and a fifty-two week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. On average, analysts expect that Compass Therapeutics, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Ratings Changes

CMPX has been the subject of several research reports. D. Boral Capital reiterated a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Jefferies Financial Group increased their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday. Finally, Leerink Partnrs lowered Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $11.17.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.